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Abstract Recently, cDNAs encoding novel RFamide-related
peptides (RFRPs) have been reported in the mammalian brains
by a gene database search and the deduced RFRPs have been
suggested to participate in neuroendocrine and pain mechanisms
in the rat. Two peptides have been predicted to be encoded in the
cDNA of rodent RFRPs. To assess precise functions of rodent
RFRPs in the brain, in the present study we identified a naturally
occurring RFRP in the rat hypothalamus by immunoaffinity
purification combined with mass spectrometry (MS). The affinity
chromatography showed that the rat hypothalamus contained
RFRP-like immunoreactivity. The immunoreactive material was
analyzed by a nanoflow electrospray ionization time-of-flight
MS followed by tandem MS analysis. The mass peak
corresponding to octadecapeptide was detected at 1010.54 m/z
([M+2H]2) and its sequence, ANMEAGTMSHFPSLPQRF-
NH2, was revealed by the fragmentation, showing a mature
form encoded in the cDNA sequence of RFRPs. The identified
endogenous RFRP will aid not only in defining its physiological
roles but also facilitate the development of its agonists and
antagonists in the rodent brain. ß 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Since the cardioexcitatory Phe-Met-Arg-Phe-NH2
(FMRFamide) was originally isolated from the ganglia of
the venus clam [1], some neuropeptides containing carboxyl-
terminal the RFamide motif have been found in several verte-
brate brains and referred to as RFamide peptides. At the ¢rst
time LPLRFamide, a chicken pentapeptide, has been puri¢ed
in the vertebrate brain [2]. Two pain modulatory neuropep-
tides FF and AF [3], prolactin-releasing peptide [4] and its ¢sh
counterpart Carassius RFamide [5] are also RFamide pep-
tides. To date, these RFamide peptides have been shown to
play many important physiological roles, such as neuroendo-
crine, behavioral, sensory and autonomic functions (see re-
views [6^8]). Recently, we have isolated and identi¢ed a novel
avian hypothalamic RFamide peptide (SIKPSAYLPLRF-
NH2) inhibiting gonadotropin release from the quail brain
and named gonadotropin-inhibitory hormone (GnIH) [9].
A cDNA encoding GnIH has also been cloned [10]. In addi-
tion, we have recently isolated the dodecapeptide
(SLKPAANLPLRF-NH2) closely related to GnIH from the
bullfrog hypothalamus [11]. This frog peptide possessed
growth hormone (GH)-releasing activity in both in vivo and
in vitro studies and was designated frog GH-releasing peptide
(fGRP) [11]. On the other hand, cDNAs of new RFamide
peptides similar to GnIH have been reported in the mamma-
lian brains by a gene database search and termed RFamide-
related peptides (RFRPs) [12]. Two deduced RFRPs have
been suggested to be present in the cDNA of mammals [12].
Hinuma et al. [12] have reported that the intracerebroventric-
ular administration of the deduced human dodecapeptide
(hRFRP-1; MPHSFANLPLRF-NH2) increases prolactin re-
lease in the rat. On the other hand, Liu et al. [13] have sup-
posed that the 37-residue RFamide peptide, which is an
N-terminal extended form of the human dodecapeptide
(hRFRP-1) [12], is one of the predicted mature RFRPs judg-
ing from the cleavage site and indicated that the rat 37-residue
peptide modulates the action of morphine. However, the iden-
ti¢cation of endogenous mature RFRPs has not been deter-
mined in mammals. We have previously found that RFRP-
like immunoreactive substances are highly concentrated in the
rodent brainstem including hypothalamus [14]. To elucidate
precise functions of RFRPs in mammals, in this study we
identi¢ed a mature endogenous RFRP from the relative small
amounts of rat hypothalami by the immunoa⁄nity chroma-
tography and mass spectrometric (MS) analyses.
2. Materials and methods
2.1. Animals and tissue samples
Sixty adult male Donryu rats at the age of 5 months were employed
in this study. The hypothalami were dissected out by ¢ne scissors and
forceps, frozen in liquid nitrogen, and kept at 380‡C until used. The
experimental protocol was approved in accordance with the Guide for
the Care and Use of Laboratory Animals prepared by Hiroshima
University, Japan.
2.2. A⁄nity puri¢cation and immunoassay
To identify an endogenous RFRP in the hypothalamus, we used the
speci¢c antibody against quail GnIH [9]. This antibody has previously
been con¢rmed to recognize speci¢cally deduced rat RFRPs [14].
The hypothalami were boiled and homogenized in 5% acetic acid as
described previously [9,11,15,16]. The homogenate was centrifuged at
15 000Ug for 20 min at 4‡C and the supernatant was collected. After
the precipitation with 75% acetone, the supernatant was passed
through a disposable C-18 cartridge column (Mega Bond-Elut; Var-
ian, Harbor, USA) and the retained material was loaded onto an
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immunoa⁄nity column chromatography. The a⁄nity chromatogra-
phy was carried out as described elsewhere [3]. The antibodies against
GnIH were conjugated to CNBr-activated Sepharose 4B as an a⁄nity
ligand. The hypothalamic extract was applied to the column at 4‡C
and the adsorbed materials were eluted with 0.3 M acetic acid con-
taining 0.1% 2-mercaptoethanol. An aliquot of each fraction (1 ml)
was analyzed by a dot immunoblot assay with the antibody against
GnIH according to our previous method [11]. The immunoreactive
fractions were concentrated and subjected to a reversed-phase high-
performance liquid chromatography (HPLC) column (ODS-80TM;
Tosoh, Tokyo, Japan) with a linear gradient of 20^40% acetonitrile
containing 0.1% tri£uoroacetic acid for 100 min at a £ow rate of
0.5 ml/min. The isolated immunoreactive substance was then sub-
jected to MS analyses as described below.
2.3. MS and peptide synthesis
After evaporation of the immunoreactive material, the residue was
dissolved in 50% methanol containing 0.1% formic acid and the mo-
lecular mass was analyzed by a nano£ow electrospray ionization time-
of-£ight MS (nano ESI-TOF-MS) (Q-TOF, Micromass UK, Wythen-
shawe, UK) as described previously [10,17]. The prospected mass
value of each deduced rat RFRP was calculated using the ProteinPro-
spector program (UCSF) and a corresponding peak was further ex-
amined in a tandem MS analysis. The needle voltage was optimized at
1000 V and the cone voltage was set at 50 V. Argon was used as the
collision gas and the energy was set at 28 V.
The peptide having the suggested sequence was synthesized by a
manual method followed by a hydrogen £uoride-anisole cleavage
and puri¢ed by reversed-phase HPLC. The synthetic peptide was
compared with the native one with regard to behavior on HPLC
and MS.
3. Results and discussion
Acetic acid extracts of rat hypothalami were passed through
a disposable C-18 reversed-phase cartridge column. The re-
tained material eluted with 60% methanol was then subjected
to an a⁄nity chromatography with the antibody cross-reacted
with deduced rat RFRPs. Immunoreactivity was measured in
the eluted fractions by a dot immunoblot assay. Immunore-
active fractions were then subjected to the reversed-phase
HPLC puri¢cation, and the eluate was fractionated every
2 min and assayed by immunoblotting. The fraction corre-
sponding to the elution time of 36^38 min showed an intense
immunoreactivity (Table 1). A puri¢ed substance was further
Table 1
Behavior of puri¢ed and synthetic peptide on HPLC and MS
Retention time on HPLC
(min)
Observed mass (m/z [M+2H]2) Calculated mass (m/z [M+2H]2)
Puri¢ed peptide 36^38 1010.54 ^
Synthetic peptide 37.2 1010.51 1010.48
Fig. 1. Fragmentation patterns of the puri¢ed substance with the observed mass number of 1010.54 m/z ([M+2H]2) by a tandem MS analysis.
The spectrum shows typical mass values of predicted octadecapeptide fragment ions. Observed N-terminal (b) and C-terminal (y) fragmentation
ions are assigned in the sequence of the octadecapeptide.
FEBS 25764 8-2-02
K. Ukena et al./FEBS Letters 512 (2002) 255^258256
examined in a MS. The mass values of predicted peptides were
previously calculated using programming software on the ba-
sis of the sequence of rat preproprotein [12]. A molecular ion
peak in the spectrum of the substance was observed at 1010.54
m/z ([M+2H]2) on the nano ESI-TOF-MS (Table 1). This
value was close to the mass number 1010.48 m/z
([M+2H]2) calculated for octadecapeptide, ANMEA-
GTMSHFPSLPQRF-NH2 (Table 1). Therefore, the sequence
was determined by a tandem MS analysis (Fig. 1). Assignment
of the observed typical fragment ions, i.e. N-terminal (b) and
C-terminal (y) ions, indicated that the amino acid sequence of
this peak was compatible with the sequence AN-
MEAGTMSHFPSLPQRF-NH2 (Fig. 1). To con¢rm the
data obtained by these structural analyses, the peptide having
the suggested sequence was synthesized and compared with
the puri¢ed peptide with regard to the retention time on
HPLC and the mass number. Both puri¢ed and synthetic
octadecapeptides showed a similar retention time on the re-
versed-phase HPLC and a similar molecular mass (Table 1).
Furthermore, the fragmentation of synthetic peptide by the
tandem MS analysis was completely coincident with that of
the puri¢ed one (data not shown).
Hinuma et al. [12] have reported that the preproprotein of
rat RFRPs contains two putative peptides (RFRP-1 and
RFRP-2). Although deduced RFRPs may have prolactin-re-
leasing and anti-opioid activities in the rat [12,13], the char-
acterization of mature RFRPs has not been investigated in
mammals. In the present study, we therefore demonstrated
that the octadecapeptide, ANMEAGTMSHFPSLPQRF-
NH2, is a mature form of RFRP-2 in the rat hypothalamus.
On the other hand, it has been speculated that RFRP-1 is a
37-amino acid residue peptide judging from the cleavage site
[13]. However, endogenous RFRP-1 remains to be character-
ized in this study. In contrast to the mammal, we have iden-
ti¢ed the novel hypothalamic RFamide peptide, GnIH [9],
and its related peptide, GnIH-RP-2 [10], in the quail brain.
Subsequently, we have isolated fGRP closely related to GnIH
from the frog hypothalamus [11]. As summarized in Table 2,
the present and previous ¢ndings [9^11] strengthen the view
that members of the novel RFamide family (RFRP and its
related peptides) possess the LPXRF-NH2 (X = L or Q) motif
at the C-terminus in both mammalian and non-mammalian
species.
We have previously found that RFRP-like immunoreactive
cell bodies and ¢bers are distributed in the regions involved in
feeding, pain and auditory systems in the mouse brain [14]. It
is therefore possible that RFRPs may participate in several
important physiological roles in rodents. On the other hand,
the study of the receptor for RFRPs is now very confused.
Hinuma et al. [12] have reported that a G protein-coupled
receptor OT7T022 is a speci¢c receptor for deduced RFRPs,
while Bonini et al. [18] have proposed the same receptor as a
receptor for another RFamide peptide, neuropeptide FF. The
sequence of neuropeptide FF, FLFQPQRF-NH2, is closely
related to the present identi¢ed octadecapeptide and their C-
terminal four amino acids are identical. To draw a ¢rm con-
clusion for the RFRP receptor, further study is needed. We
believe that the present ¢ndings can contribute to future stud-
ies concerning the physiological roles of an endogenous
RFRP, the properties of its receptors and the development
of its agonists and antagonists in the mammalian brain.
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